TargetBeta
NPM1
nucleophosmin 1 · also B23, NPM
2 programs in company-led studies act on NPM1, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 312 running | ALK, EML4, MET, MST1R, ROS1 | ChEMBL |
| Autologous HLA-A*02:01-restricted Mutant NPM1-directed TCR-expressing T-lymphocytes BSB-2002rule | BlueSphere Bio | phase 1 | 10 running | – | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Lymphoma, 1 program
- Lymphoma, Large-Cell, Anaplastic, 1 program
- Neoplasms, 1 program
- Uveal Melanoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 21, 2028Crizotinib · Pfizer · phase 4 · NCT05160922
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.